FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dariusz Pawlak

Research Profile

Procedures

Renal Dialysis

Chemicals & Drugs

Disorders

Living Beings

Concepts & Ideas

Biological Markers

Physiology

Co-author Network

Publications

TOP 3
Krystyna Pawlak; Dariusz Rozkiewicz; Michal Mysliwiec; Dariusz Pawlak
YKL-40 in hemodialyzed patients with and without cardiovascular complications - the enhancement by the coexistence of the seropositivity against hepatitis C virus infection.
Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?
Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: the effect of dialysis treatment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dariusz Pawlak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Krystyna Pawlak; Dariusz Rozkiewicz; Michal Mysliwiec; Dariusz Pawlak
YKL-40 in hemodialyzed patients with and without cardiovascular complications - the enhancement by the coexistence of the seropositivity against hepatitis C virus infection.
Cytokine 2013;62(1):75-80.
2013: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?
Life sciences 2013;92(4-5):253-8.
2012: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
The alteration in Cu/Zn superoxide dismutase and adhesion molecules concentrations in diabetic patients with chronic kidney disease: the effect of dialysis treatment.
Diabetes research and clinical practice 2012;98(2):264-70.
2012: Krystyna Pawlak; Blanka Ulazka; Michal Mysliwiec; Dariusz Pawlak
Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
Translational research : the journal of laboratory and clinical medicine 2012;160(5):346-54.
2012: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Oxidized LDL to autoantibodies against oxLDL ratio - the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients.
Atherosclerosis 2012;224(1):252-7.
2012: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.
Thrombosis research 2012;129(6):704-9.
2011: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Interleukin-21 in hemodialyzed patients: association with the etiology of chronic kidney disease and the seropositivity against hepatitis C virus infection.
Clinical biochemistry 2011;44(17-18):1416-20.
2011: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis.
Clinical biochemistry 2011;44(10-11):838-43.
2010: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients.
Clinical biochemistry 2010;43(18):1393-8.
2010: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Hepatitis C virus seropositivity and TNF superfamily receptors: sCD40, sFas--the new putative determinants of endothelial dysfunction in haemodialysis patients.
Thrombosis research 2010;126(5):393-8.
2010: Anna Tankiewicz-Kwedlo; Dariusz Pawlak; Tomasz Domaniewski; Wlodzimierz Buczko
Effect of erythropoietin, 5-fluorouracil and SN-38 on the growth of DLD-1 cells.
Pharmacological reports : PR 2010;62(5):926-37.
2010: Krystyna Pawlak; Anna Kowalewska; Michal Mysliwiec; Dariusz Pawlak
3-hydroxyanthranilic acid is independently associated with monocyte chemoattractant protein-1 (CCL2) and macrophage inflammatory protein-1beta (CCL4) in patients with chronic kidney disease.
Clinical biochemistry 2010;43(13-14):1101-6.
2010: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
Thrombosis research 2010;125(2):e40-5.
2010: E Gulaj; Krystyna Pawlak; Barbara Bien; Dariusz Pawlak
Kynurenine and its metabolites in Alzheimer's disease patients.
Advances in medical sciences 2010;55(2):204-11.
2010: Krystyna Pawlak; M Myśliwiec; Dariusz Pawlak
Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients.
Advances in medical sciences 2010;55(2):196-203.
2010: Krystyna Pawlak; Janina Tankiewicz; Michal Mysliwiec; Dariusz Pawlak
Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients.
Nephron. Clinical practice 2010;115(4):c251-8.
2010: Krystyna Pawlak; Agnieszka Buraczewska-Buczko; Michal Mysliwiec; Dariusz Pawlak
Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
The American journal of the medical sciences 2010;339(1):5-9.
2009: Krystyna Pawlak; Tomasz Domaniewski; Michal Mysliwiec; Dariusz Pawlak
Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.
Thrombosis research 2009;124(4):452-7.
2009: Krystyna Pawlak; Szymon Brzosko; Michal Mysliwiec; Dariusz Pawlak
Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.
Atherosclerosis 2009;204(2):561-6.
2009: Krystyna Pawlak; Tomasz Domaniewski; Michal Mysliwiec; Dariusz Pawlak
The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.
Atherosclerosis 2009;204(1):309-14.
2008: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure.
Cytokine 2008;43(1):98-101.
2008: Joanna Pawlak; Janusz Dziecioł; Maria Mantur; Dariusz Pawlak
Megakaryocytes and platelets in experimentally induced renovascular hypertension (2K1C) in rats.
Postȩpy higieny i medycyny doświadczalnej (Online) 2008;62():241-8.
2008: Iwona Kucharewicz; Irena Kasacka; Dariusz Pawlak; Anna Tankiewicz-Kwedlo; Barbara Mroczko; Wlodzimierz Buczko; Anna Bodzenta-Lukaszyk
The concentration of kynurenine in rat model of asthma.
Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2008;46(2):199-203.
2008: Krystyna Pawlak; Krzysztof Zolbach; Jacek Borawski; Michal Mysliwiec; Oksana Kovalchuk; Lech Chyczewski; Dariusz Pawlak
Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
Thrombosis research 2008;123(1):166-70.
2008: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Thrombosis research 2008;122(3):328-35.
2008: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Thrombosis research 2008;121(6):787-91.
2008: Krystyna Pawlak; Dariusz Pawlak; Michal Myśliwiec
Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Thrombosis research 2008;121(4):543-8.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
LIGHT--a new member of the TNF superfamily in the plasma, dialysate and urine of uremic patients; the impact of residual diuresis and presence of viral hepatitis.
Clinical biochemistry 2007;40(16-17):1240-4.
2007: Krystyna Pawlak; Michal Mysliwiec; Dariusz Pawlak
Chronic viral hepatitis and iron affect the plasma levels of LIGHT--a new member of the TNF superfamily in uraemic haemodialyzed patients.
Cytokine 2007;39(3):201-6.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(5):467-71.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes.
Nephron. Clinical practice 2007;107(1):c20-5.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Thrombosis research 2007;120(6):797-803.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
American journal of nephrology 2007;27(3):221-5.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Thrombosis research 2007;120(6):871-6.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.
Clinical biochemistry 2007;40(1-2):81-5.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Thrombosis research 2007;119(4):475-80.
2007: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients.
Atherosclerosis 2007;190(1):199-204.
2006: Krystyna Pawlak; Dariusz Pawlak; Michal Myśliwiec
Inflammation but not oxidative stress is associated with beta-chemokine levels and prevalence of cardiovascular disease in uraemic patients.
Cytokine 2006;35(5-6):258-62.
2006: Krystyna Pawlak; Dariusz Pawlak; Szymon Brzosko; Michal Mysliwiec
Carotid atherosclerosis is associated with enhanced beta-chemokine levels in patients on continuous ambulatory peritoneal dialysis.
Atherosclerosis 2006;186(1):146-51.
2006: Krystyna Pawlak; Dariusz Pawlak; Michał Myśliwiec
Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients.
Medical science monitor : international medical journal of experimental and clinical research 2006;12(4):CR181-5.
2006: Anna Tankiewicz; P Buczko; IJ Szarmach; I Kasacka; Dariusz Pawlak
The concentration of anthranilic acid in saliva of orthodontic appliances.
Advances in medical sciences 2006;51 Suppl 1():31-3.
2006: Anna Tankiewicz; D Dziemiańczyk; P Buczko; IJ Szarmach; Stanislawa Zyta Grabowska; Dariusz Pawlak
Tryptophan and its metabolites in patients with oral squamous cell carcinoma: preliminary study.
Advances in medical sciences 2006;51 Suppl 1():221-4.
2006: IJ Szarmach; I Kasacka; P Buczko; Anna Tankiewicz; Dariusz Pawlak
Oral cavity status and IgE level in orthodontic patients.
Advances in medical sciences 2006;51 Suppl 1():210-2.
2006: I Kasacka; IJ Szarmach; P Buczko; Anna Tankiewicz; Dariusz Pawlak
Preliminary evaluation of saliva composition in allergic patients subjected to orthodontic treatment; morphological examination.
Advances in medical sciences 2006;51 Suppl 1():55-8.
2006: I Kasacka; IJ Szarmach; P Buczko; Anna Tankiewicz; Dariusz Pawlak
Preliminary evaluation of morphological parameters of the saliva in patients undergoing orthodontic treatment.
Advances in medical sciences 2006;51 Suppl 1():52-4.
2006: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients.
American journal of nephrology 2006;26(5):497-502.
2006: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Thrombosis research 2006;117(5):517-22.
2005: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.
Clinical biochemistry 2005;38(8):700-5.
2005: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
Cytokine 2005;31(1):18-24.
2005: Anna Tankiewicz; Dariusz Pawlak; K Pawlak; D Szewc; M Myśliwiec; Wlodzimierz Buczko
Anthranilic acid-uraemic toxin damaged red cell's membrane.
International urology and nephrology 2005;37(3):621-7.
2004: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
American journal of nephrology 2004;24(6):635-40.
2004: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients.
Thrombosis and haemostasis 2004;92(3):646-53.
2004: Sebastian Pawlak; Dariusz Pawlak; Wlodzimierz Buczko
[Hypoxia involvement in erythropoiesis regulation--a new insight].
Przegla̧d lekarski 2004;61(12):1415-9.
2004: W Bogusłowicz; Dorota Lemancewicz; Dariusz Pawlak; J Dziecioł
Histomorphometry of marrow megakaryocytes in experimental uraemia in rats.
Roczniki Akademii Medycznej w Białymstoku (1995) 2004;49 Suppl 1():159-60.
2004: Krystyna Pawlak; Dariusz Pawlak; Michal Mysliwiec
Oxidative stress influences CC-chemokine levels in hemodialyzed patients.
Nephron. Physiology 2004;96(4):p105-12.
2004: Krystyna Pawlak; Beata Naumnik; Szymon Brzósko; Dariusz Pawlak; Michał Myśliwiec
Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients.
American journal of nephrology 2004;24(1):154-61.
2003: Dariusz Pawlak; Anna Tankiewicz; Tomasz Matys; Wlodzimierz Buczko
Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2003;54(2):175-89.
2003: Dariusz Pawlak; Mariusz Koda; Sebastian Pawlak; Slawomir Wolczynski; Wlodzimierz Buczko
Contribution of quinolinic acid in the development of anemia in renal insufficiency.
American journal of physiology. Renal physiology 2003;284(4):F693-700.
2003: Anna Tankiewicz; Dariusz Pawlak; Joanna Topczewska-Bruns; Wlodzimierz Buczko
Kidney and liver kynurenine pathway enzymes in chronic renal failure.
Advances in experimental medicine and biology 2003;527():409-14.
2003: Dariusz Pawlak; Mariusz Koda; Sawomir Wołczyński; Michal Myśliwiec; Wlodzimierz Buczko
Mechanism of inhibitory effect of 3-hydroxykynurenine on erythropoiesis in patients with renal insufficiency.
Advances in experimental medicine and biology 2003;527():375-80.
2003: Joanna Topczewska-Bruns; Dariusz Pawlak; Anna Tankiewicz; Ewa Chabielska; Wlodzimierz Buczko
Kynurenine metabolism in central nervous system in experimental chronic renal failure.
Advances in experimental medicine and biology 2003;527():177-82.
2002: Iwona Kucharewicz; Robert Pawlak; Tomasz Matys; Dariusz Pawlak; Wlodzimierz Buczko
Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7).
Hypertension 2002;40(5):774-9.
2002: Joanna Topczewska-Bruns; Dariusz Pawlak; Ewa Chabielska; Anna Tankiewicz; Wlodzimierz Buczko
Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.
Brain research bulletin 2002;58(4):423-8.
2002: Piotr Myśliwiec; Dariusz Pawlak; M Myśliwiec; Wlodzimierz Buczko
Endogenous neurotoxine-quinolinic acid is increased in renal allograft recipients.
Transplantation proceedings 2002;34(2):598-600.
2002: Dariusz Pawlak; Anna Tankiewicz; Piotr Mysliwiec; Wlodzimierz Buczko
Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure.
Nephron 2002;90(3):328-35.
2001: Dariusz Pawlak; Anna Tankiewicz; Wlodzimierz Buczko
Kynurenine and its metabolites in the rat with experimental renal insufficiency.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2001;52(4 Pt 2):755-66.
2001: J Andrzejewska-Buczko; Dariusz Pawlak; Anna Tankiewicz; Tomasz Matys; Wlodzimierz Buczko
Possible involvement of kynurenamines in the pathogenesis of cataract in diabetic patients.
Medical science monitor : international medical journal of experimental and clinical research 2001;7(4):742-5.
2001: Joanna Topczewska-Bruns; Anna Tankiewicz; Dariusz Pawlak; Wlodzimierz Buczko
Behavioral changes in the course of chronic renal insufficiency in rats.
Polish journal of pharmacology 2001;53(3):263-9.
2001: Dariusz Pawlak; K Pawlak; Jolanta Malyszko; Michal Mysliwiec; Wlodzimierz Buczko
Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.
International urology and nephrology 2001;33(2):399-404.
2001: Anna Tankiewicz; Dariusz Pawlak; Wlodzimierz Buczko
[Enzymes of the kynurenine pathway].
Postȩpy higieny i medycyny doświadczalnej 2001;55(5):715-31.
2000: Iwona Kucharewicz; Ewa Chabielska; Dariusz Pawlak; Tomasz Matys; R Rólkowski; Wlodzimierz Buczko
The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2000;1(3):268-72.
2000: Ewa Chabielska; Tomasz Matys; Iwona Kucharewicz; Dariusz Pawlak; R Rólkowski; Wlodzimierz Buczko
The involvement of AT(2)-receptor in the antithrombotic effect of losartan in renal hypertensive rats.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2000;1(3):263-7.
2000: Dariusz Pawlak; E Malczyk; Janusz S Darewicz; Arsalan Azzadin; Wlodzimierz Buczko
Platelet serotonergic mechanisms in patients with cancer of the urinary bladder.
Thrombosis research 2000;98(5):367-74.
2000: Dariusz Pawlak; Y Takada; T Urano; A Takada
Serotonergic and kynurenic pathways in rats exposed to foot shock.
Brain research bulletin 2000;52(3):197-205.
2000: P Myśliwiec; Dariusz Pawlak
[Kynurenic pathway in health and disease].
Postȩpy higieny i medycyny doświadczalnej 2000;54(2):239-52.
1999: E Malczyk; Barbara Darewicz; Dariusz Pawlak; Janusz S Darewicz; Wlodzimierz Buczko
Investigations of urinary lead concentration in patients with urinary bladder carcinoma.
International urology and nephrology 1999;31(5):661-3.
1998: Jacek S Malyszko; J Malyszko; Dariusz Pawlak; Wlodzimierz Buczko; M Myśliwiec
Hemostasis, platelet functions, serotonin and serum lipids during omega-3 fatty acid treatment in patients with glomerulonephritis.
Nephron 1998;80(1):94-6.
1998: Ewa Chabielska; Robert Pawlak; J Golatowski; R Rółkowski; Dariusz Pawlak; Wlodzimierz Buczko
Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats.
Thrombosis research 1998;90(6):271-8.
1998: Dariusz Pawlak; K Pawlak; Ewa Chabielska; J Małyszko; A Takada; M Myśliwiec; Wlodzimierz Buczko
A potent 5-hydroxytryptamine receptor (5-HT2A) antagonist, DV-7028, delays arterial thrombosis development in rats.
Thrombosis research 1998;90(6):259-70.
1997: A Rydzewski; J Małyszko; Jacek Borawski; Dariusz Pawlak; Arsalan Azzadin; Wlodzimierz Buczko; M Myśliwiec
Altered circadian rhythm of platelet aggregation in hemodialyzed patients.
Nephron 1997;77(3):365-7.
1997: A Rydzewski; J Małyszko; Jacek Borawski; Dariusz Pawlak; K Adamcewicz; Wlodzimierz Buczko; M Myśliwiec
[Altered circadian rhythm of platelet aggregation in patients on longterm hemodialysis].
Przegla̧d lekarski 1997;54(3):167-70.
1996: Dariusz Pawlak; Barbara Malinowska; T Wollny; G Godlewski; Wlodzimierz Buczko
Lack of the specific influence of histamine and histamine H1, H2 and H3 receptor ligands on the serotonin uptake and release in rat blood platelets.
Polish journal of pharmacology 1996;48(6):615-20.
1996: J Malyszko; Jacek S Malyszko; Dariusz Pawlak; K Pawlak; Wlodzimierz Buczko; Michal Mysliwiec
Hemostasis, platelet function and serotonin in acute and chronic renal failure.
Thrombosis research 1996;83(5):351-61.
1996: Dariusz Pawlak; J Malyszko; Jacek S Malyszko; K Pawlak; Wlodzimierz Buczko; Michal Mysliwiec
Peripheral serotonergic system in uremia.
Thrombosis research 1996;83(2):189-94.
1996: J Malyszko; Dariusz Pawlak; K Pawlak; Jacek S Malyszko; Wlodzimierz Buczko; A Azzudin; Michal Mysliwiec
Platelet aggregation and peripheral serotonergic system in kidney transplant recipients treated with cyclosporine.
Transplantation proceedings 1996;28(3):1954-7.
1996: D Krygicz; Arsalan Azzadin; Robert Pawlak; J S Małyszko; Dariusz Pawlak; M Myśliwiec; Wlodzimierz Buczko
Cyclosporine A affects serotonergic mechanisms in uremic rats.
Polish journal of pharmacology 1996;48(3):351-4.
1996: J Małyszko; J S Małyszko; Dariusz Pawlak; K Pawlak; A Rydzewski; M Myśliwiec; Wlodzimierz Buczko
Comprehensive study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome.
Polish journal of pharmacology 1996;48(2):191-5.
1996: Dariusz Pawlak; J Małyszko; M Myśliwiec; A Takada; Wlodzimierz Buczko
Effect of DV-7028, a novel serotonin 5-HT2 receptor antagonist on the cardiovascular system in rats.
Acta physiologica Hungarica 1996;84(3):325-6.
1996: Dariusz Pawlak; J Małyszko; M Myśliwiec; A Takada; Wlodzimierz Buczko
Influence of MCI-9042, a novel 5-HT2 receptor blocker on blood vessels of the rat.
Acta physiologica Hungarica 1996;84(3):323-4.
1995: D Morelowska-Spierzak; Dariusz Pawlak; Wlodzimierz Buczko
Influence of captopril on the serotonin-induced vasopressor effect in tail artery isolated from two-kidney, one-clip renal hypertensive rats.
Polish journal of pharmacology 1995;47(5):417-22.
1993: Dariusz Pawlak; D Morelowska-Spierzak; Arsalan Azzadin; K Wróbel; Wlodzimierz Buczko
Lack of effect of acetaldehyde on the cardiovascular system in rats.
Alcohol and alcoholism (Oxford, Oxfordshire) 1993;28(5):529-33.
1993: Dariusz Pawlak; Ewa Chabielska; Wlodzimierz Buczko
Influence of acetaldehyde on some serotonergic mechanisms in rat blood platelets.
Polish journal of pharmacology 1993;45(1):59-66.
1993: Wlodzimierz Buczko; Barbara Malinowska; M H Pietraszek; Dariusz Pawlak; Ewa Chabielska
Influence of Tołpa Peat Preparation on haemostasis in rats.
Acta poloniae pharmaceutica 1993;50(6):507-11.
1992: Barbara Malinowska; Dariusz Pawlak; Wlodzimierz Buczko
Influence of DAU 6215, a novel 5-HT3 receptor antagonist, on the cardiovascular system in anaesthetized and pithed rats.
Agents and actions 1992;36(3-4):230-6.
1992: Dariusz Pawlak; D Krygicz; Ewa Chabielska; Wlodzimierz Buczko
Influence of acetaldehyde on the vasopressor effect of serotonin in pithed rats.
Alcohol and alcoholism (Oxford, Oxfordshire) 1992;27(4):367-72.
1992: D Morelowska; Ewa Chabielska; Dariusz Pawlak; Arsalan Azzadin; A Białkowska; D Krygicz; Wlodzimierz Buczko
Effect of captopril on serotonergic mechanisms in two-kidney, one-clip renal hypertensive rats.
Polish journal of pharmacology and pharmacy 1992;44(4):365-72.
1992: Arsalan Azzadin; A Bialkowska; Dariusz Pawlak; Ewa Chabielska; M Mazerska; Michal Mysliwiec; Wlodzimierz Buczko
Serotonin is involved in some effects of erythropoietin.
Thrombosis research 1992;65(4-5):657-61.
1992: Dariusz Pawlak; Barbara Malinowska; Wlodzimierz Buczko
Cardiovascular effects of acetaldehyde in pithed rats.
Pharmacology 1992;45(2):83-9.
1990: Barbara Malinowska; M Pietraszek; Ewa Chabielska; Dariusz Pawlak; Wlodzimierz Buczko
The effect of ethanol and serotonin on blood vessels of the rat.
Polish journal of pharmacology and pharmacy 1990;42(4):333-42.
1990: Barbara Malinowska; Dariusz Pawlak; Ewa Chabielska; Wlodzimierz Buczko
Influence of acute and chronic ethanol administration on the vasopressor effect of serotonin in pithed rats.
Pharmacology 1990;41(2):91-7.
1989: Barbara Malinowska; Dariusz Pawlak; Ewa Chabielska; Wlodzimierz Buczko
Cardiovascular effects of ethanol in anaesthetized, conscious and pithed rats.
Drug and alcohol dependence 1989;24(1):51-6.